<inglise> Directive 98/44/EC of the European Parliament and of the Council of July 1998 on the legal protection of biotechnological inve tions July 1998 on the legal protection of biotechnological inventions </inglise>
<eesti> EUROOPA PARLAMENDI JA N&Otilde;UKOGU DIREKTIIV 98/44/E&Uuml; biotehnoloogialeiutiste &otilde;iguskaitse kohta 6. juuli 1998 </eesti>
<inglise> THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, </inglise>
<eesti> EUROOPA PARLAMENT JA EUROOPA LIIDU N&Otilde;UKOGU, </eesti>
<inglise> Having regard to the Treaty establishing the European Community, and in particular Article 100a thereof, </inglise>
<eesti> v&otilde;ttes arvesse Euroopa &Uuml;henduse asutamislepingut, eriti selle artiklit 100a, </eesti>
<inglise> Having regard to the proposal from the Commission (1), </inglise>
<eesti> v&otilde;ttes arvesse komisjoni ettepanekut, (1) </eesti>
<inglise> Having regard to the opinion of the Economic and Social Committee (2), </inglise>
<eesti> v&otilde;ttes arvesse majandus- ja sotsiaalkomitee arvamust, (2) </eesti>
<inglise> Acting in accordance with the procedure laid down in Article 189b of the Treaty (3), </inglise>
<eesti> toimides vastavalt asutamislepingu artiklis 189b s&auml;testatud menetlusele (3) </eesti>
<inglise> (1) Whereas biotechnology and genetic engineering are playing an increasingly important role in a broad range of industries and the protection of biotechnological inventions will certainly be of fundamental importance for the Community's industrial development; </inglise>
<eesti> ning arvestades, et: 1) biotehnoloogia ja geenitehnika etendavad paljudes t&ouml;&ouml;stusvaldkondades j&auml;rjest t&auml;htsamat osa ja biotehnoloogialeiutiste kaitse on &uuml;henduse t&ouml;&ouml;stuslikule arengule kindlasti elut&auml;htis; </eesti>
<inglise> (2) Whereas, in particular in the field of genetic engineering, research and development require a considerable amount of high-risk investment and therefore only adequate legal protection can make them profitable; </inglise>
<eesti> 2) eriti geenitehnika valdkonnas n&otilde;uab uurimis- ja arendustegevus arvestataval m&auml;&auml;ral suure riskiteguriga investeeringuid, mille tasuvuse saab tagada ainult piisav &otilde;iguskaitse; </eesti>
<inglise> (3) Whereas effective and harmonised protection throughout the Member States is essential in order to maintain and encourage investment in the field of biotechnology; </inglise>
<eesti> 3) tulemuslik ja &uuml;htlustatud kaitse k&otilde;igis liikmesriikides on eriti oluline biotehnoloogia valdkonda tehtavate investeeringute soodustamiseks ja j&auml;tkuvuse tagamiseks; </eesti>
<inglise> (4) Whereas following the European Parliament's rejection of the joint text, approved by the Conciliation Committee, for a European Parliament and Council Directive on the legal protection of biotechnological inventions (4), the European Parliament and the Council have determined that the legal protection of biotechnological inventions requires clarification; </inglise>
<eesti> 4) p&auml;rast seda, kui Euroopa Parlament l&uuml;kkas tagasi lepituskomitee heakskiidetud biotehnoloogialeiutiste &otilde;iguskaitset k&auml;sitleva Euroopa Parlamendi ja n&otilde;ukogu direktiivi &uuml;histeksti, (4) on Euroopa Parlament ja n&otilde;ukogu t&otilde;denud, et biotehnoloogialeiutiste &otilde;iguskaitse vajab selgitamist; </eesti>
<inglise> (5) Whereas differences exist in the legal protection of biotechnological inventions offered by the laws and practices of the different Member States; whereas such differences could create barriers to trade and hence impede the proper functioning of the internal market; </inglise>
<eesti> 5) biotehnoloogialeiutiste &otilde;iguskaitset pakkuvates eri liikmesriikide seadustes ja tavades on erinevusi; niisugused erinevused v&otilde;ivad p&otilde;hjustada kaubandust&otilde;kkeid ja seega takistada siseturu n&otilde;uetekohast toimimist; </eesti>
<inglise> (6) Whereas such differences could well become greater as Member States adopt new and different legislation and administrative practices, or whereas national case-law interpreting such legislation develops differently; </inglise>
<eesti> 6) niisugused erinevused v&otilde;ivad veelgi suureneda, kui liikmesriigid v&otilde;tavad vastu uued ja teistsugused &otilde;igusaktid ja haldustavad v&otilde;i kui niisuguseid &otilde;igusakte t&otilde;lgendav siseriiklik kohtupraktika areneb eri suunas; </eesti>
<inglise> (7) Whereas uncoordinated development of national laws on the legal protection of biotechnological inventions in the Community could lead to further disincentives to trade, to the detriment of the industrial development of such inventions and of the smooth operation of the internal market; </inglise>
<eesti> 7) biotehnoloogialeiutiste &otilde;iguskaitset k&auml;sitlevate siseriiklike &otilde;igusaktide koosk&otilde;lastamata areng &uuml;henduses v&otilde;ib kaubandust veelgi enam p&auml;rssida, kahjustada niisuguste leiutiste t&ouml;&ouml;stuslikku arendamist ja siseturu t&otilde;rgeteta toimimist; </eesti>
<inglise> (8) Whereas legal protection of biotechnological inventions does not necessitate the creation of a separate body of law in place of the rules of national patent law; whereas the rules of national patent law remain the essential basis for the legal protection of biotechnological inventions given that they must be adapted or added to in certain specific respects in order to take adequate account of technological developments involving biological material which also fulfil the requirements for patentability; </inglise>
<eesti> 8) biotehnoloogialeiutiste &otilde;iguskaitse ei eelda omaette &otilde;igusnormide loomist siseriikliku patendi&otilde;iguse normide asemele; siseriikliku patendi&otilde;iguse normid j&auml;&auml;vad biotehnoloogialeiutiste &otilde;iguskaitse peamiseks aluseks, ometi tuleb neid teatud punktides muuta v&otilde;i t&auml;iendada, et piisavalt arvesse v&otilde;tta bioloogilise materjaliga seotud tehnoloogilist arengut, mis vastab ka patentsusen&otilde;uetele; </eesti>
<inglise> (9) Whereas in certain cases, such as the exclusion from patentability of plant and animal varieties and of essentially biological processes for the production of plants and animals, certain concepts in national laws based upon international patent and plant variety conventions have created uncertainty regarding the protection of biotechnological and certain microbiological inventions; whereas harmonisation is necessary to clarify the said uncertainty; </inglise>
<eesti> 9) teatavatel juhtudel, nagu taimesortide ja loomaliikide ning taime- ja loomakasvatuse olemuselt bioloogiliste protsesside patentsuse v&auml;listamise puhul, on teatavad rahvusvahelistel patendi- ja sordikaitsekonventsioonidel p&otilde;hinevad siseriiklike &otilde;igusaktide m&otilde;isted p&otilde;hjustanud ebakindlust seoses biotehnoloogia- ja teatavate mikrobioloogialeiutiste kaitsega; nimetatud ebakindluse k&otilde;rvaldamiseks on vajalik &uuml;htlustamine; </eesti>
<inglise> (10) Whereas regard should be had to the potential of the development of biotechnology for the environment and in particular the utility of this technology for the development of methods of cultivation which are less polluting and more economical in their use of ground; whereas the patent system should be used to encourage research into, and the application of, such processes; </inglise>
<eesti> 10) arvesse peaks v&otilde;tma biotehnoloogia arengupotentsiaali keskkonna vallas, eriti selle tehnoloogia kasulikkust v&auml;hem saastavate ja pinnakasutuse osas majanduslikult otstarbekamate taimekasvatusmeetodite v&auml;ljat&ouml;&ouml;tamisel; niisuguste meetodite uurimise ja kohaldamise soodustamiseks tuleks kasutada patendis&uuml;steemi; </eesti>
<inglise> (11) Whereas the development of biotechnology is important to developing countries, both in the field of health and combating major epidemics and endemic diseases and in that of combating hunger in the world; whereas the patent system should likewise be used to encourage research in these fields; whereas international procedures for the dissemination of such technology in the Third World and to the benefit of the population groups concerned should be promoted; </inglise>
<eesti> 11) biotehnoloogia arendamine on arengumaadele oluline nii tervishoiu valdkonnas kui ka peamiste epideemiate ja endeemsete haiguste vastu v&otilde;itlemisel, samuti n&auml;lja vastu v&otilde;itlemisel maailmas; samamoodi tuleks patendis&uuml;steemi kasutada uurimist&ouml;&ouml; soodustamiseks nendes valdkondades kasutada; tuleks edendada rahvusvahelisi menetlusi sellise tehnoloogia levitamiseks Kolmandas Maailmas ja asjaomaste rahvastikur&uuml;hmade h&uuml;vanguks; </eesti>
<inglise> (12) Whereas the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) (5) signed by the European Community and the Member States, has entered into force and provides that patent protection must be guaranteed for products and processes in all areas of technology; </inglise>
<eesti> 12) Euroopa &Uuml;henduse ja liikmesriikide allakirjutatud intellektuaalomandi &otilde;iguste kaubandusaspektide leping (TRIP) (5) on j&otilde;ustunud ja selles on s&auml;testatud, et patendikaitse peab olema tagatud k&otilde;ikide tehnoloogiavaldkondade toodetele ja meetoditele; </eesti>
<inglise> (13) Whereas the Community's legal framework for the protection of biotechnological inventions can be limited to laying down certain principles as they apply to the patentability of biological material as such, such principles being intended in particular to determine the difference between inventions and discoveries with regard to the patentability of certain elements of human origin, to the scope of protection conferred by a patent on a biotechnological invention, to the right to use a deposit mechanism in addition to written descriptions and lastly to the option of obtaining non-exclusive compulsory licences in respect of interdependence between plant varieties and inventions, and conversely; </inglise>
<eesti> 13) &uuml;henduse biotehnoloogialeiutiste kaitse &otilde;iguslik raamistik v&otilde;ib piirduda teatud p&otilde;him&otilde;tete s&auml;testamisega, mis kehtivad bioloogilise materjali kui sellise patentsuse suhtes, kusjuures niisuguste p&otilde;him&otilde;tete eesm&auml;rk on eriti m&auml;&auml;ratleda erinevus leiutiste ja avastuste vahel seoses teatavate inimp&auml;ritoluga elementide patentsusega; peale selle v&otilde;ib &otilde;iguslik raamistik piirduda biotehnoloogialeiutisele antud patendiga etten&auml;htud kaitse ulatusega, &otilde;igusega kasutada lisaks kirjalikele kirjeldustele ka tagatismehhanismi ja l&otilde;puks v&otilde;imalusega saada mitteainu&otilde;iguslikke sundlitsentse taimesortide ja leiutiste vastastikuse s&otilde;ltuvuse puhul ja &uuml;mberp&ouml;&ouml;rdult; </eesti>
<inglise> (14) Whereas a patent for invention does not authorise the holder to implement that invention, but merely entitles him to prohibit third parties from exploiting it for industrial and commercial purposes; whereas, consequently, substantive patent law cannot serve to replace or render superfluous national, European or international law which may impose restrictions or prohibitions or which concerns the monitoring of research and of the use or commercialisation of its results, notably from the point of view of the requirements of public health, safety, environmental protection, animal welfare, the preservation of genetic diversity and compliance with certain ethical standards; </inglise>
<eesti> 14) leiutise patent ei anna selle valdajale luba leiutist rakendada, vaid annab talle &uuml;ksnes &otilde;iguse keelata kolmandatel isikutel leiutise kasutamise t&ouml;&ouml;stuslikel ja kaubanduslikel eesm&auml;rkidel; seet&otilde;ttu ei saa patendi&otilde;igus asendada v&otilde;i muuta &uuml;learuseks siseriiklikke, Euroopa v&otilde;i rahvusvahelisi &otilde;igusakte, millega v&otilde;idakse m&auml;&auml;rata piiranguid v&otilde;i keelde v&otilde;i mis k&auml;sitlevad uurimist&ouml;&ouml; ning selle tulemuste kasutamist v&otilde;i nendega kauplemist eelk&otilde;ige rahva tervise, ohutuse, keskkonnakaitse, loomakaitse, geneetilise mitmekesisuse s&auml;ilitamise ja teatavate eetikanormide j&auml;rgimise osas; </eesti>
<inglise> (15) Whereas no prohibition or exclusion exists in national or European patent law (Munich Convention) which precludes a priori the patentability of biological matter; </inglise>
<eesti> 15) siseriiklikus v&otilde;i Euroopa patendi&otilde;iguses (M&uuml;ncheni konventsioon) ei ole keeldu ega erandit, mis ette v&auml;listaks bioloogilise materjali patentsuse; </eesti>
<inglise> (16) Whereas patent law must be applied so as to respect the fundamental principles safeguarding the dignity and integrity of the person; whereas it is important to assert the principle that the human body, at any stage in its formation or development, including germ cells, and the simple discovery of one of its elements or one of its products, including the sequence or partial sequence of a human gene, cannot be patented; whereas these principles are in line with the criteria of patentability proper to patent law, whereby a mere discovery cannot be patented; </inglise>
<eesti> 16) patendi&otilde;igust tuleks kohaldada nii, et j&auml;rgitaks isikuv&auml;&auml;rikust ja -puutumatust kaitsvaid p&otilde;him&otilde;tteid; oluline on maksma panna p&otilde;him&otilde;te, et inimorganismi selle &uuml;ksk&otilde;ik millises kujunemis- v&otilde;i arenguastmes, sealhulgas looterakke, samuti selle elemendi v&otilde;i produkti, kaasa arvatud inimgeeni nukleotiidj&auml;rjestuse v&otilde;i osalise nukleotiidj&auml;rjestuse lihtsat avastamist ei saa patentida; need p&otilde;him&otilde;tted on koosk&otilde;las patendi&otilde;igusele omaste patentsuskriteeriumidega, mille kohaselt pelgalt avastust ei saa patentida; </eesti>
<inglise> (17) Whereas significant progress in the treatment of diseases has already been made thanks to the existence of medicinal products derived from elements isolated from the human body and/or otherwise produced, such medicinal products resulting from technical processes aimed at obtaining elements similar in structure to those existing naturally in the human body and whereas, consequently, research aimed at obtaining and isolating such elements valuable to medicinal production should be encouraged by means of the patent system; </inglise>
<eesti> 17) t&auml;nu inimorganismist eraldatud ja/v&otilde;i muul viisil toodetud elementidest saadud ravimite olemasolule on haiguste ravimisel juba tehtud olulisi edusamme; niisugused ravimid on toodetud tehniliste meetoditega, mille eesm&auml;rk on saada inimorganismis loomulikult olemasolevate elementide struktuurile sarnase struktuuriga elemente; seet&otilde;ttu tuleks niisuguste ravimitootmisele v&auml;&auml;rtuslike elementide saamisele ja eraldamisele suunatud uurimist&ouml;&ouml;d patendis&uuml;steemi abil soodustada; </eesti>
<inglise> (18) Whereas, since the patent system provides insufficient incentive for encouraging research into and production of biotechnological medicines which are needed to combat rare or 'orphan' diseases, the Community and the Member States have a duty to respond adequately to this problem; </inglise>
<eesti> 18) et patendis&uuml;steem ei erguta piisavalt harvaesinevate v&otilde;i v&auml;hest t&auml;helepanu p&auml;lvivate haiguste vastu v&otilde;itlemiseks vajalike biotehnoloogiliste ravimite uurimist ja tootmist, on &uuml;hendus ja liikmesriigid kohustatud sellele probleemile asjakohaselt reageerima; </eesti>
<inglise> (19) Whereas account has been taken of Opinion No 8 of the Group of Advisers on the Ethical Implications of Biotechnology to the European Commission; </inglise>
<eesti> 19) Euroopa Komisjoni biotehnoloogia eetika n&otilde;ustajate t&ouml;&ouml;r&uuml;hma arvamust nr 8 on arvesse v&otilde;etud; </eesti>
<inglise> (20) Whereas, therefore, it should be made clear that an invention based on an element isolated from the human body or otherwise produced by means of a technical process, which is susceptible of industrial application, is not excluded from patentability, even where the structure of that element is identical to that of a natural element, given that the rights conferred by the patent do not extend to the human body and its elements in their natural environment; </inglise>
<eesti> 20) seet&otilde;ttu tuleks t&auml;psustada, et inimorganismist eraldatud v&otilde;i muul viisil tehnilise meetodi abil toodetud elemendil p&otilde;hinevat leiutist, mis v&otilde;imaldaks t&ouml;&ouml;stuslikku kasutust, ei j&auml;eta patentsusest v&auml;lja, isegi kui sellel elemendil on loodusliku elemendiga &uuml;hesugune struktuur; patendiga antud &otilde;igused ei laiene siiski inimorganismile ja selle elementidele nende loomulikus keskkonnas; </eesti>
<inglise> (21) Whereas such an element isolated from the human body or otherwise produced is not excluded from patentability since it is, for example, the result of technical processes used to identify, purify and classify it and to reproduce it outside the human body, techniques which human beings alone are capable of putting into practice and which nature is incapable of accomplishing by itself; </inglise>
<eesti> 21) niisugust inimorganismist eraldatud v&otilde;i muul viisil toodetud elementi ei j&auml;eta patentsusest v&auml;lja, sest see on n&auml;iteks saadud tema m&auml;&auml;ratlemiseks, puhastamiseks, liigitamiseks ning v&auml;ljaspool inimorganismi paljundamiseks kasutatud tehniliste meetodite abil, mida ainult inimene suudab rakendada, loodus aga mitte; </eesti>
<inglise> (22) Whereas the discussion on the patentability of sequences or partial sequences of genes is controversial; whereas, according to this Directive, the granting of a patent for inventions which concern such sequences or partial sequences should be subject to the same criteria of patentability as in all other areas of technology: novelty, inventive step and industrial application; whereas the industrial application of a sequence or partial sequence must be disclosed in the patent application as filed; </inglise>
<eesti> 22) arutelu geenide nukleotiidj&auml;rjestuse v&otilde;i osalise nukleotiidj&auml;rjestuse patentsuse &uuml;le tekitab lahkarvamusi; k&auml;esoleva direktiivi kohaselt tuleks niisuguseid nukleotiidj&auml;rjestusi v&otilde;i osalisi nukleotiidj&auml;rjestusi k&auml;sitlevatele leiutistele patendi andmisel arvesse v&otilde;tta samu patentsuskriteeriume nagu k&otilde;igi teiste tehnoloogiavaldkondade puhul: uudsust, leiutustase ja t&ouml;&ouml;stuslikku kasutust; nukleotiidj&auml;rjestuse v&otilde;i osalise nukleotiidj&auml;rjestuse t&ouml;&ouml;stuslikku kasutust tuleb esitatud patenditaotluses konkreetselt kirjeldada; </eesti>
<inglise> (23) Whereas a mere DNA sequence without indication of a function does not contain any technical information and is therefore not a patentable invention; </inglise>
<eesti> 23) pelgalt DNA nukleotiidj&auml;rjestus, mille puhul &uuml;lesannet &auml;ra ei n&auml;idata, ei sisalda mingit tehnilist teavet ega ole seet&otilde;ttu patenditav leiutis; </eesti>
<inglise> (24) Whereas, in order to comply with the industrial application criterion it is necessary in cases where a sequence or partial sequence of a gene is used to produce a protein or part of a protein, to specify which protein or part of a protein is produced or what function it performs; </inglise>
<eesti> 24) t&ouml;&ouml;stusliku kasutuse kriteeriumile vastamiseks on juhtudel, kui geeni nukleotiidj&auml;rjestust v&otilde;i osalist nukleotiidj&auml;rjestust kasutatakse proteiini v&otilde;i proteiini osa tootmiseks, vaja t&auml;psustada, missugust proteiini v&otilde;i proteiini osa toodetakse v&otilde;i missugust &uuml;lesannet see t&auml;idab; </eesti>
<inglise> (25) Whereas, for the purposes of interpreting rights conferred by a patent, when sequences overlap only in parts which are not essential to the invention, each sequence will be considered as an independent sequence in patent law terms; </inglise>
<eesti> 25) kui nukleotiidj&auml;rjestused kattuvad ainult nende osade puhul, mis leiutise seisukohast ei ole olulised, peetakse patendiga antud &otilde;iguste t&otilde;lgendamise eesm&auml;rgil patendi&otilde;iguse kohaselt iga nukleotiidj&auml;rjestust iseseisvaks nukleotiidj&auml;rjestuseks; </eesti>
<inglise> (26) Whereas if an invention is based on biological material of human origin or if it uses such material, where a patent application is filed, the person from whose body the material is taken must have had an opportunity of expressing free and informed consent thereto, in accordance with national law; </inglise>
<eesti> 26) kui leiutise alus on inimp&auml;ritoluga bioloogiline materjal v&otilde;i kui temas kasutatakse niisugust materjali, peab patenditaotluse esitamise korral olema isikul, kelle organismist materjal on v&otilde;etud, olnud v&otilde;imalus koosk&otilde;las siseriikliku seadusega v&auml;ljendada selleks oma vaba ja eelinformatsioonil p&otilde;hinevat n&otilde;usolekut; </eesti>
<inglise> (27) Whereas if an invention is based on biological material of plant or animal origin or if it uses such material, the patent application should, where appropriate, include information on the geographical origin of such material, if known; whereas this is without prejudice to the processing of patent applications or the validity of rights arising from granted patents; </inglise>
<eesti> 27) kui leiutise alus on taimse v&otilde;i loomse p&auml;ritoluga bioloogiline materjal v&otilde;i kui temas kasutatakse niisugust materjali, peaks patenditaotlus vajaduse korral sisaldama ka teavet niisuguse materjali geograafilise p&auml;ritolu kohta, kui see on teada; see ei piira patenditaotluste l&auml;bit&ouml;&ouml;tamist ega v&auml;ljastatud patentidest tulenevate &otilde;iguste kehtivust; </eesti>
<inglise> (28) Whereas this Directive does not in any way affect the basis of current patent law, according to which a patent may be granted for any new application of a patented product; </inglise>
<eesti> 28) k&auml;esolev direktiiv ei m&otilde;juta mingil viisil kehtiva patendi&otilde;iguse aluseid, mille kohaselt patendi v&otilde;ib anda patenditud toote igale uuele rakendusele; </eesti>
<inglise> (29) Whereas this Directive is without prejudice to the exclusion of plant and animal varieties from patentability; whereas on the other hand inventions which concern plants or animals are patentable provided that the application of the invention is not technically confined to a single plant or animal variety; </inglise>
<eesti> 29) k&auml;esolev direktiiv ei piira taimesortide ja loomaliikide patentsusest v&auml;ljaj&auml;tmist; teiselt poolt on taimi v&otilde;i loomi k&auml;sitlevad leiutised patenditavad, kui leiutise rakendamine ei piirdu tehniliselt &uuml;he taimesordi v&otilde;i loomaliigiga. </eesti>
<inglise> (30) Whereas the concept 'plant variety' is defined by the legislation protecting new varieties, pursuant to which a variety is defined by its whole genome and therefore possesses individuality and is clearly distinguishable from other varieties; </inglise>
<eesti> 30) m&otilde;iste "taimesort" on m&auml;&auml;ratletud uusi sorte kaitsvates &otilde;igusaktides, mille kohaselt sordile on iseloomulik tema genoomi terviklikkus ja seet&otilde;ttu on ta individuaalne ning selgesti teistest sortidest eristatav; </eesti>
<inglise> (31) Whereas a plant grouping which is characterised by a particular gene (and not its whole genome) is not covered by the protection of new varieties and is therefore not excluded from patentability even if it comprises new varieties of plants; </inglise>
<eesti> 31) taimer&uuml;hm, mida iseloomustab mingi eriline geen (ja mitte terviklik genoom), ei kuulu uute sortide kaitse alla ja seet&otilde;ttu ei j&auml;eta seda patentsusest v&auml;lja isegi juhul, kui sellesse kuulub uusi taimesorte; </eesti>
<inglise> (32) Whereas, however, if an invention consists only in genetically modifying a particular plant variety, and if a new plant variety is bred, it will still be excluded from patentability even if the genetic modification is the result not of an essentially biological process but of a biotechnological process; </inglise>
<eesti> 32) kui leiutise puhul on tegemist ainult teatava taimesordi geneetilise muutmisega ja kui aretatakse uus taimesort, j&auml;etakse leiutis patentsusest v&auml;lja isegi sel juhul, kui geneetiline muudatus ei ole olemuselt bioloogilise, vaid on biotehnoloogilise meetodi tulemus; </eesti>
<inglise> (33) Whereas it is necessary to define for the purposes of this Directive when a process for the breeding of plants and animals is essentially biological; </inglise>
<eesti> 33) k&auml;esoleva direktiivi kohaldamiseks on vaja kindlaks m&auml;&auml;rata, millal taimede ja loomade aretamise meetod on olemuselt bioloogiline; </eesti>
<inglise> (34) Whereas this Directive shall be without prejudice to concepts of invention and discovery, as developed by national, European or international patent law; </inglise>
<eesti> 34) k&auml;esolev direktiiv ei piira siseriiklikus, Euroopa v&otilde;i rahvusvahelises patendi&otilde;iguses m&auml;&auml;ratletud leiutise ja avastuse m&otilde;isteid; </eesti>
<inglise> (35) Whereas this Directive shall be without prejudice to the provisions of national patent law whereby processes for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body are excluded from patentability; </inglise>
<eesti> 35) k&auml;esolev direktiiv ei piira siseriikliku patendi&otilde;iguse s&auml;tteid, mille kohaselt inim- v&otilde;i loomorganismi kirurgilised v&otilde;i teraapilised ravimeetodid ning inim- v&otilde;i loomorganismidel kasutatavad diagnostikameetodid ei ole patenditavad; </eesti>
<inglise> (36) Whereas the TRIPs Agreement provides for the possibility that members of the World Trade Organisation may exclude from patentability inventions, the prevention within their territory of the commercial exploitation of which is necessary to protect ordre public or morality, including to protect human, animal or plant life or health or to avoid serious prejudice to the environment, provided that such exclusion is not made merely because the exploitation is prohibited by their law; </inglise>
<eesti> 36) TRIP-leping s&auml;testab v&otilde;imaluse, et Maailma Kaubandusorganisatsiooni liikmed v&otilde;ivad patentsusest v&auml;lja j&auml;tta leiutised, mille kaubanduslik kasutamine nende territooriumil on keelatud vajadusest kaitsta avalikku korda v&otilde;i moraali, sealhulgas kaitsta inimeste, loomade ja taimede elu ning tervist v&otilde;i v&auml;ltida t&otilde;siseid keskkonnakahjustusi, tingimusel et selline v&auml;listamine ei toimu ainu&uuml;ksi seep&auml;rast, et niisugune v&auml;listamine on nende &otilde;igusega keelatud; </eesti>
<inglise> (37) Whereas the principle whereby inventions must be excluded from patentability where their commercial exploitation offends against ordre public or morality must also be stressed in this Directive; </inglise>
<eesti> 37) k&auml;esolevas direktiivis tuleb r&otilde;hutada ka p&otilde;him&otilde;tet, mille kohaselt leiutised ei ole patenditavad, kui nende kaubanduslik kasutus rikub avalikku korda v&otilde;i moraali; </eesti>
<inglise> (38) Whereas the operative part of this Directive should also include an illustrative list of inventions excluded from patentability so as to provide national courts and patent offices with a general guide to interpreting the reference to ordre public and morality; whereas this list obviously cannot presume to be exhaustive; whereas processes, the use of which offend against human dignity, such as processes to produce chimeras from germ cells or totipotent cells of humans and animals, are obviously also excluded from patentability; </inglise>
<eesti> 38) k&auml;esoleva direktiivi regulatiivosa peaks sisaldama ka patentsusest v&auml;listatud leiutiste n&auml;idisloetelu, et anda siseriiklikele kohtutele ja patendiametitele &uuml;ldine juhend avalikule korrale ja moraalile viitamise t&otilde;lgendamiseks; ilmselt ei saa eeldada, et see loetelu oleks ammendav; loomulikult ei ole patenditav ka inimv&auml;&auml;rikust rikkuvate meetodite kasutamine, nagu inimeste ja loomade loote- v&otilde;i totipotentsetest rakkudest kim&auml;&auml;ride tootmine; </eesti>
<inglise> (39) Whereas ordre public and morality correspond in particular to ethical or moral principles recognised in a Member State, respect for which is particularly important in the field of biotechnology in view of the potential scope of inventions in this field and their inherent relationship to living matter; whereas such ethical or moral principles supplement the standard legal examinations under patent law regardless of the technical field of the invention; </inglise>
<eesti> 39) avalik kord ja moraal vastavad eelk&otilde;ige liikmesriigis tunnustatud eetika- v&otilde;i moraalip&otilde;him&otilde;tetele, mille j&auml;rgimine on eriti oluline biotehnoloogia valdkonnas, silmas pidades selle valdkonna leiutiste ulatust ja neile omast seotust elusainega; niisugused eetika- v&otilde;i moraalip&otilde;him&otilde;tted t&auml;iendavad patendi&otilde;iguse kohast standardset &otilde;iguslikku kontrolli hoolimata sellest, missugusesse tehnilisse valdkonda leiutis kuulub; </eesti>
<inglise> (40) Whereas there is a consensus within the Community that interventions in the human germ line and the cloning of human beings offends against ordre public and morality; whereas it is therefore important to exclude unequivocally from patentability processes for modifying the germ line genetic identity of human beings and processes for cloning human beings; </inglise>
<eesti> 40) &uuml;henduses ollakse &uuml;ht meelt selles, et inimloote arengusse sekkumine ja inimeste kloonimine rikuvad avalikku korda ja moraali; seet&otilde;ttu on oluline patentsusest selges&otilde;naliselt v&auml;lja j&auml;tta inimloote geneetilise samasuse muutmise ja inimeste kloonimise meetodid; </eesti>
<inglise> (41) Whereas a process for cloning human beings may be defined as any process, including techniques of embryo splitting, designed to create a human being with the same nuclear genetic information as another living or deceased human being; </inglise>
<eesti> 41) inimese kloonimise meetodit v&otilde;ib m&auml;&auml;ratleda kui mis tahes meetodit, embr&uuml;o osadeks jaotamine kaasa arvatud, mille eesm&auml;rk on luua inimene, kel on samasugune rakutuuma geeniteave, nagu m&otilde;nel teisel elaval v&otilde;i surnud inimesel; </eesti>
<inglise> (42) Whereas, moreover, uses of human embryos for industrial or commercial purposes must also be excluded from patentability; whereas in any case such exclusion does not affect inventions for therapeutic or diagnostic purposes which are applied to the human embryo and are useful to it; </inglise>
<eesti> 42) peale selle tuleb patentsusest v&auml;lja j&auml;tta inimese embr&uuml;ote kasutamine t&ouml;&ouml;stuslikel v&otilde;i kaubanduslikel eesm&auml;rkidel; igal juhul ei m&otilde;juta niisugune v&auml;ljaj&auml;tmine terapeutilise v&otilde;i diagnostilise eesm&auml;rgiga leiutisi, mida kohaldatakse inimese embr&uuml;o puhul ja mis on sellele kasulikud; </eesti>
<inglise> (43) Whereas pursuant to Article F(2) of the Treaty on European Union, the Union is to respect fundamental rights, as guaranteed by the European Convention for the Protection of Human Rights and Fundamental Freedoms signed in Rome on 4 November 1950 and as they result from the constitutional traditions common to the Member States, as general principles of Community law; </inglise>
<eesti> 43) vastavalt Euroopa Liidu lepingu artikli F l&otilde;ikele 2 austab liit p&otilde;hi&otilde;igusi kui &uuml;henduse &otilde;iguse &uuml;ldp&otilde;him&otilde;tteid, nagu need on tagatud inim&otilde;iguste ja p&otilde;hivabaduste kaitse Euroopa konventsiooniga, mis on alla kirjutatud Roomas 4. novembril 1950, ning nagu need tulenevad liikmesriikide &uuml;hesugustest riigi&otilde;iguslikest tavadest; </eesti>
<inglise> (44) Whereas the Commission's European Group on Ethics in Science and New Technologies evaluates all ethical aspects of biotechnology; whereas it should be pointed out in this connection that that Group may be consulted only where biotechnology is to be evaluated at the level of basic ethical principles, including where it is consulted on patent law; </inglise>
<eesti> 44) k&otilde;ikidele biotehnoloogia eetikaaspektidele annab hinnangu komisjoni teaduse ja uute tehnoloogiate eetika Euroopa t&ouml;&ouml;r&uuml;hm; sellega seoses tuleks r&otilde;hutada, et r&uuml;hmaga v&otilde;ib konsulteerida, kaasa arvatud patendi&otilde;iguse osas, ainult juhul, kui biotehnoloogiat tuleb hinnata eetika alusp&otilde;him&otilde;tete tasandil; </eesti>
<inglise> (45) Whereas processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit in terms of research, prevention, diagnosis or therapy to man or animal, and also animals resulting from such processes, must be excluded from patentability; </inglise>
<eesti> 45) loomade geneetilist samasust muutvad ja neile t&otilde;en&auml;oliselt kannatusi p&otilde;hjustavad meetodid, millest ei ole ei inimesele ega loomale mingit olulist meditsiinilist kasu ei uurimist&ouml;&ouml;, ennetamise, diagnoosi ega teraapia valdkonnas, samuti niisuguste meetodite abil saadud loomad ei ole patenditavad; </eesti>
<inglise> (46) Whereas, in view of the fact that the function of a patent is to reward the inventor for his creative efforts by granting an exclusive but time-bound right, and thereby encourage inventive activities, the holder of the patent should be entitled to prohibit the use of patented self-reproducing material in situations analogous to those where it would be permitted to prohibit the use of patented, non-self-reproducing products, that is to say the production of the patented product itself; </inglise>
<eesti> 46) pidades silmas, et patendi &uuml;lesanne on t&auml;htajalise ainu&otilde;iguse andmise teel h&uuml;vitada leiutajale tema loovad pingutused ja sellega soodustada leiutustegevust, peaks patendi valdajal olema &otilde;igus keelata patenditud isepaljuneva materjali kasutamist olukordades, mis on samalaadsed olukordadega, mille puhul lubataks keelata muude kui isepaljunevate patenditud produktide kasutamine, s.t patenditud produkti enda valmistamine; </eesti>
<inglise> (47) Whereas it is necessary to provide for a first derogation from the rights of the holder of the patent when the propagating material incorporating the protected invention is sold to a farmer for farming purposes by the holder of the patent or with his consent; whereas that initial derogation must authorise the farmer to use the product of his harvest for further multiplication or propagation on his own farm; whereas the extent and the conditions of that derogation must be limited in accordance with the extent and conditions set out in Council Regulation (EC) No 2100/94 of 27 July 1994 on Community plant variety rights (6); </inglise>
<eesti> 47) on vaja s&auml;testada esimene erand patendi valdaja &otilde;igustest, kui patendi valdaja m&uuml;&uuml;b v&otilde;i tema n&otilde;usolekul m&uuml;&uuml;akse patendiga kaitstud leiutist sisaldav paljundusmaterjal talumajapidamise tarbeks talupidajale; see esialgne erand peab lubama talupidajal kasutada talumajapidamises oma saagi toodet edasiseks generatiivseks v&otilde;i vegetatiivseks paljundamiseks; selle erandi m&auml;&auml;r ja tingimused peavad olema piiratud vastavalt &uuml;henduse taimesordi&otilde;igusi k&auml;sitlevas n&otilde;ukogu 27. juuli 1994. aasta m&auml;&auml;ruses (E&Uuml;) nr 2100/94 (6) s&auml;testatud m&auml;&auml;rale ja tingimustele; </eesti>
<inglise> (48) Whereas only the fee envisaged under Community law relating to plant variety rights as a condition for applying the derogation from Community plant variety rights can be required of the farmer; </inglise>
<eesti> 48) talupidajalt v&otilde;idakse &uuml;henduse taimesordi&otilde;igustest erandi tegemise tingimusena n&otilde;uda ainult &uuml;henduse taimesordi&otilde;igusi k&auml;sitlevatest &otilde;igusaktidest tulenevat tasu; </eesti>
<inglise> (49) Whereas, however, the holder of the patent may defend his rights against a farmer abusing the derogation or against a breeder who has developed a plant variety incorporating the protected invention if the latter fails to adhere to his commitments; </inglise>
<eesti> 49) patendi valdaja v&otilde;ib siiski oma &otilde;igusi kaitsta erandit kuritarvitava talupidaja v&otilde;i patendiga kaitstud leiutist sisaldava taimesordi aretanud sordiaretaja suhtes, kui viimane ei t&auml;ida oma kohustusi; </eesti>
<inglise> (50) Whereas a second derogation from the rights of the holder of the patent must authorise the farmer to use protected livestock for agricultural purposes; </inglise>
<eesti> 50) teine erand patendi valdaja &otilde;igustest peab lubama talupidajal kasutada patendiga kaitstud karja p&otilde;llumajanduslikel eesm&auml;rkidel; </eesti>
<inglise> (51) Whereas the extent and the conditions of that second derogation must be determined by national laws, regulations and practices, since there is no Community legislation on animal variety rights; </inglise>
<eesti> 51) k&otilde;nealuse teise erandi m&auml;&auml;r ja tingimused peavad olema kindlaks m&auml;&auml;ratud siseriiklike &otilde;igusaktide ja tavadega, sest loomaliigikaitset k&auml;sitlevad &uuml;henduse &otilde;igusaktid puuduvad; </eesti>
<inglise> (52) Whereas, in the field of exploitation of new plant characteristics resulting from genetic engineering, guaranteed access must, on payment of a fee, be granted in the form of a compulsory licence where, in relation to the genus or species concerned, the plant variety represents significant technical progress of considerable economic interest compared to the invention claimed in the patent; </inglise>
<eesti> 52) geenitehnika abil saadud uute taimeomaduste kasutamisele tuleb tasu eest tagada juurdep&auml;&auml;s kohustusliku litsentsiga, kui k&otilde;nealuse perekonna v&otilde;i liigi osas esindab taimesort m&auml;rkimisv&auml;&auml;rset tehnilist arengut, millest seoses patenditaotluses osutatud leiutisega johtub oluline majanduslik huvi; </eesti>
<inglise> (53) Whereas, in the field of the use of new plant characteristics resulting from new plant varieties in genetic engineering, guaranteed access must, on payment of a fee, be granted in the form of a compulsory licence where the invention represents significant technical progress of considerable economic interest; </inglise>
<eesti> 53) uutest taimesortidest tulenevate uute taimeomaduste kasutamisele geenitehnikas tuleb tasu eest tagada juurdep&auml;&auml;s kohustusliku litsentsiga, kui leiutis esindab m&auml;rkimisv&auml;&auml;rset tehnilist arengut, millest johtub oluline majanduslik huvi; </eesti>
<inglise> (54) Whereas Article 34 of the TRIPs Agreement contains detailed provisions on the burden of proof which is binding on all Member States; whereas, therefore, a provision in this Directive is not necessary; </inglise>
<eesti> 54) TRIP-lepingu artikkel 34 sisaldab &uuml;ksikasjalikke s&auml;tteid t&otilde;endamiskohustuse kohta, mis on siduv k&otilde;ikides liikmesriikides; seet&otilde;ttu ei ole k&auml;esolevas direktiivis niisugust s&auml;tet tarvis; </eesti>
<inglise> (55) Whereas following Decision 93/626/EEC (7) the Community is party to the Convention on Biological </inglise>
<eesti> 55) p&auml;rast otsust 93/626/EM&Uuml; (7) on &uuml;hendus 5. juuni 1992. aasta bioloogilise mitmekesisuse konventsiooni osalisriik; </eesti>
<inglise> Diversity of 5 June 1992; whereas, in this regard, Member States must give particular weight to Article 3 and Article 8(j), the second sentence of Article 16(2) and Article 16(5) of the Convention when bringing into force the laws, regulations and administrative provisions necessary to comply with this Directive; </inglise>
<eesti> sellega seoses peavad liikmesriigid k&auml;esolevale direktiivile vastavuse saavutamiseks vajalike &otilde;igus- ja haldusnormide j&otilde;ustamisel eriti t&auml;htsaks pidama konventsiooni artiklit 3 ja artikli 8 punkti j, artikli 16 l&otilde;ike 2 teist lauset ja artikli 16 l&otilde;iget 5; </eesti>
<inglise> (56) Whereas the Third Conference of the Parties to the Biodiversity Convention, which took place in November 1996, noted in Decision III/17 that 'further work is required to help develop a common appreciation of the relationship between intellectual property rights and the relevant provisions of the TRIPs Agreement and the Convention on Biological Diversity, in particular on issues relating to technology transfer and conservation and sustainable use of biological diversity and the fair and equitable sharing of benefits arising out of the use of genetic resources, including the protection of knowledge, innovations and practices of indigenous and local communities embodying traditional lifestyles relevant for the conservation and sustainable use of biological diversity', </inglise>
<eesti> 56) bioloogilise mitmekesisuse konventsiooni osalisriikide kolmas konverents novembris 1996 m&auml;rkis otsuses III/17, et "on vaja j&auml;tkata t&ouml;&ouml;d, et aidata v&auml;lja t&ouml;&ouml;tada TRIP-lepingu ja bioloogilise mitmekesisuse konventsiooni vastavate s&auml;tete ja intellektuaalomandi &otilde;iguste vaheliste seoste &uuml;hine hinnang eriti k&uuml;simustes, mis on seotud tehnoloogia siirde ning bioloogilise mitmekesisuse kaitse ja s&auml;&auml;stva kasutamise ning geneetiliste ressursside kasutamisest tuleneva kasu &otilde;iglase ja erapooletu jaotamisega, kaasa arvatud traditsioonilisi eluviise kehastavatele omamaistele ja kohalikele kogukondadele kuuluvate bioloogilise mitmekesisuse kaitse ja s&auml;&auml;stva kasutuse seisukohast oluliste teadmiste, uuenduste ja meetmete kaitse", </eesti>
<inglise> HAVE ADOPTED THIS DIRECTIVE: </inglise>
<eesti> ON VASTU V&Otilde;TNUD K&Auml;ESOLEVA DIREKTIIVI. </eesti>
<inglise> CHAPTER I </inglise>
<eesti> I PEAT&Uuml;KK </eesti>
<inglise> Patentability </inglise>
<eesti> Patentsus </eesti>
<inglise> Article 1 </inglise>
<eesti> Artikkel 1 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Member States shall protect biotechnological inventions under national patent law. </inglise>
<eesti> Liikmesriigid kaitsevad biotehnoloogialeiutisi siseriikliku patendi&otilde;iguse alusel. </eesti>
<inglise> They shall, if necessary, adjust their national patent law to take account of the provisions of this Directive. </inglise>
<eesti> Vajaduse korral kohandavad nad oma siseriiklikku patendi&otilde;igust vastavalt k&auml;esoleva direktiivi s&auml;tetele. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> This Directive shall be without prejudice to the obligations of the Member States pursuant to international agreements, and in particular the TRIPs Agreement and the Convention on Biological Diversity. </inglise>
<eesti> K&auml;esolev direktiiv ei piira kohustusi, mis liikmesriikidel on vastavalt rahvusvahelistele kokkulepetele, eriti TRIP-lepingule ja bioloogilise mitmekesisuse konventsioonile. </eesti>
<inglise> Article 2 </inglise>
<eesti> Artikkel 2 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> For the purposes of this Directive, </inglise>
<eesti> K&auml;esoleva direktiivi kohaldamisel kasutatakse j&auml;rgmisi m&otilde;isteid: </eesti>
<inglise> (a) 'biological material' means any material containing genetic information and capable of reproducing itself or being reproduced in a biological system; </inglise>
<eesti> a) bioloogiline materjal - igasugune geneetilist teavet sisaldav materjal, mis on v&otilde;imeline isepaljunemiseks v&otilde;i mida on v&otilde;imalik paljundada mingis bioloogilises s&uuml;steemis; </eesti>
<inglise> (b) 'microbiological process' means any process involving or performed upon or resulting in microbiological material. </inglise>
<eesti> b) mikrobioloogiline meetod - igasugune meetod, mille puhul kasutatakse mikrobioloogilist materjali, mille objektiks on mikrobioloogiline materjal v&otilde;i mille tulemusena tekib mikrobioloogiline materjal. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> A process for the production of plants or animals is essentially biological if it consists entirely of natural phenomena such as crossing or selection. </inglise>
<eesti> Taimede v&otilde;i loomade aretamise meetod on olemuselt bioloogiline, kui see p&otilde;hineb t&auml;ielikult looduslikel n&auml;htustel nagu ristamisel v&otilde;i valikul. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> The concept of 'plant variety' is defined by Article 5 of Regulation (EC) No 2100/94. </inglise>
<eesti> M&otilde;iste "taimesort" on m&auml;&auml;ratletud m&auml;&auml;ruse (E&Uuml;) nr 2100/94 artiklis 5. </eesti>
<inglise> Article 3 </inglise>
<eesti> Artikkel 3 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> For the purposes of this Directive, inventions which are new, which involve an inventive step and which are susceptible of industrial application shall be patentable even if they concern a product consisting of or containing biological material or a process by means of which biological material is produced, processed or used. </inglise>
<eesti> K&auml;esoleva direktiivi kohaselt v&otilde;ib leiutisi, mis on uued, omavad leiurustaset ja v&otilde;imaldavad t&ouml;&ouml;stuslikku kasutust, patentida isegi sel juhul, kui nad k&auml;sitlevad toodet, mis koosneb bioloogilisest materjalist v&otilde;i sisaldab seda, v&otilde;i meetodit, mille abil bioloogilist materjali toodetakse, t&ouml;&ouml;deldakse v&otilde;i kasutatakse. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Biological material which is isolated from its natural environment or produced by means of a technical process may be the subject of an invention even if it previously occurred in nature. </inglise>
<eesti> Tehnilise meetodi abil loomulikust keskkonnast eraldatud v&otilde;i toodetud bioloogiline materjal v&otilde;ib olla leiutise objekt isegi sel juhul, kui ta on varem looduses esinenud. </eesti>
<inglise> Article 4 </inglise>
<eesti> Artikkel 4 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> The following shall not be patentable: </inglise>
<eesti> Patendiga ei kaitsta: </eesti>
<inglise> (a) plant and animal varieties; </inglise>
<eesti> a) taimesordid ja loomaliigid; </eesti>
<inglise> (b) essentially biological processes for the production of plants or animals. </inglise>
<eesti> b) olemuselt bioloogilised taimede v&otilde;i loomade aretamise meetodid. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Inventions which concern plants or animals shall be patentable if the technical feasibility of the invention is not confined to a particular plant or animal variety. </inglise>
<eesti> Taimi v&otilde;i loomi k&auml;sitlevad leiutised on patentsed, kui nende tehniline teostatavus ei piirdu teatava taimesordi v&otilde;i loomaliigiga. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> Paragraph 1(b) shall be without prejudice to the patentability of inventions which concern a microbiological or other technical process or a product obtained by means of such a process. </inglise>
<eesti> L&otilde;ike 1 punkt b ei piira nende leiutiste patentsust, mis k&auml;sitlevad m&otilde;nd mikrobioloogilist v&otilde;i muud tehnilist meetodit v&otilde;i niisuguse meetodi abil saadud toodet. </eesti>
<inglise> Article 5 </inglise>
<eesti> Artikkel 5 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> The human body, at the various stages of its formation and development, and the simple discovery of one of its elements, including the sequence or partial sequence of a gene, cannot constitute patentable inventions. </inglise>
<eesti> Inimorganism selle kujunemise ja arengu mitmesugustes astmetes ja m&otilde;ne selle elemendi, sealhulgas geeni nukleotiidj&auml;rjestuse v&otilde;i osalise nukleotiidj&auml;rjestuse lihtne avastamine ei saa endast kujutada patentset leiutist. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> An element isolated from the human body or otherwise produced by means of a technical process, including the sequence or partial sequence of a gene, may constitute a patentable invention, even if the structure of that element is identical to that of a natural element. </inglise>
<eesti> Inimorganismist eraldatud v&otilde;i muul viisil tehnilise meetodi abil valmistatud element, sealhulgas geeni nukleotiidj&auml;rjestus v&otilde;i osaline nukleotiidj&auml;rjestus v&otilde;ib endast kujutada patentset leiutist isegi sel juhul, kui selle elemendi struktuur on samasugune kui looduslikul elemendil. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> The industrial application of a sequence or a partial sequence of a gene must be disclosed in the patent application. </inglise>
<eesti> Geeni nukleotiidj&auml;rjestuse v&otilde;i osalise nukleotiidj&auml;rjestuse t&ouml;&ouml;stuslikku kasutust tuleb kirjeldada patenditaotluses. </eesti>
<inglise> Article 6 </inglise>
<eesti> Artikkel 6 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Inventions shall be considered unpatentable where their commercial exploitation would be contrary to ordre public or morality; however, exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation. </inglise>
<eesti> Leiutisi peetakse patenditavaks, kui nende kaubanduslik kasutus oleks vastuolus avaliku korra v&otilde;i moraaliga; sellest hoolimata ei loeta kasutust vastuolus olevaks &uuml;ksnes selle t&otilde;ttu, et see on &otilde;igus-v&otilde;i haldusnormiga keelatud. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> On the basis of paragraph 1, the following, in particular, shall be considered unpatentable: </inglise>
<eesti> L&otilde;ike 1 alusel ei loeta patentseteks eriti: </eesti>
<inglise> (a) processes for cloning human beings; </inglise>
<eesti> a) inimeste kloonimise meetodeid; </eesti>
<inglise> (b) processes for modifying the germ line genetic identity of human beings; </inglise>
<eesti> b) inimloote geneetilise samasuse muutmise meetodeid; </eesti>
<inglise> (c) uses of human embryos for industrial or commercial purposes; </inglise>
<eesti> c) inimese embr&uuml;ote kasutamist t&ouml;&ouml;stuslikel v&otilde;i kaubanduslikel eesm&auml;rkidel; </eesti>
<inglise> (d) processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes. </inglise>
<eesti> d) loomade geneetilist samasust muutvaid ja neile t&otilde;en&auml;oliselt kannatusi p&otilde;hjustavaid meetodeid, millest ei ole ei inimesele ega loomale mingit olulist meditsiinilist kasu, samuti niisuguste meetodite tulemusel saadud loomi. </eesti>
<inglise> Article 7 </inglise>
<eesti> Artikkel 7 </eesti>
<inglise> The Commission's European Group on Ethics in Science and New Technologies evaluates all ethical aspects of biotechnology. </inglise>
<eesti> Komisjoni teaduse ja uute tehnoloogiate eetika Euroopa t&ouml;&ouml;r&uuml;hm annab hinnangu k&otilde;ikidele biotehnoloogia eetikaaspektidele. </eesti>
<inglise> CHAPTER II </inglise>
<eesti> II PEAT&Uuml;KK </eesti>
<inglise> Scope of protection </inglise>
<eesti> Kaitse ulatus </eesti>
<inglise> Article 8 </inglise>
<eesti> Artikkel 8 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> The protection conferred by a patent on a biological material possessing specific characteristics as a result of the invention shall extend to any biological material derived from that biological material through propagation or multiplication in an identical or divergent form and possessing those same characteristics. </inglise>
<eesti> Leiutise tulemusel eriomadusi omavale bioloogilisele materjalile patendiga antud kaitse h&otilde;lmab iga sellest bioloogilisest materjalist vegetatiivse v&otilde;i generatiivse paljundamise teel saadud bioloogilist samases v&otilde;i erinevas vormis olevat samade omadustega materjali. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The protection conferred by a patent on a process that enables a biological material to be produced possessing specific characteristics as a result of the invention shall extend to biological material directly obtained through that process and to any other biological material derived from the directly obtained biological material through propagation or multiplication in an identical or divergent form and possessing those same characteristics. </inglise>
<eesti> Leiutise tulemusel eriomadusi omavat bioloogilist materjali toota v&otilde;imaldavale meetodile patendiga antud kaitse h&otilde;lmab selle meetodi abil otse saadud bioloogilist materjali ja iga muud sellest bioloogilisest materjalist vegetatiivse v&otilde;i generatiivse paljundamise teel saadud samases v&otilde;i erinevas vormis olevat samade omadustega bioloogilist materjali. </eesti>
<inglise> Article 9 </inglise>
<eesti> Artikkel 9 </eesti>
<inglise> The protection conferred by a patent on a product containing or consisting of genetic information shall extend to all material, save as provided in Article 5(1), in which the product in incorporated and in which the genetic information is contained and performs its function. </inglise>
<eesti> Geneetilist teavet sisaldavale v&otilde;i sellest koosnevale tootele patendiga antud kaitse h&otilde;lmab kogu materjali, millesse toodet on lisatud ja milles sisaldub oma &uuml;lesannet t&auml;itev geneetiline teave, kui artikli 5 l&otilde;ikest 1 ei tulene teisiti. </eesti>
<inglise> Article 10 </inglise>
<eesti> Artikkel 10 </eesti>
<inglise> The protection referred to in Articles 8 and 9 shall not extend to biological material obtained from the propagation or multiplication of biological material placed on the market in the territory of a Member State by the holder of the patent or with his consent, where the multiplication or propagation necessarily results from the application for which the biological material was marketed, provided that the material obtained is not subsequently used for other propagation or multiplication. </inglise>
<eesti> Artiklites 8 ja 9 viidatud kaitse ei h&otilde;lma patendi valdaja poolt v&otilde;i tema n&otilde;usolekul liikmesriigis turule viidud, bioloogilise materjali generatiivse v&otilde;i vegetatiivse paljundusega saadud bioloogilist materjali, kui generatiivne v&otilde;i vegetatiivne paljundus tuleneb vahetult rakendusest, milleks bioloogiline materjal turustati, tingimusel et saadud materjali ei kasutata edaspidi muuks generatiivseks v&otilde;i vegetatiivseks paljundamiseks. </eesti>
<inglise> Article 11 </inglise>
<eesti> Artikkel 11 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> By way of derogation from Articles 8 and 9, the sale or other form of commercialisation of plant propagating material to a farmer by the holder of the patent or with his consent for agricultural use implies authorisation for the farmer to use the product of his harvest for propagation or multiplication by him on his own farm, the extent and conditions of this derogation corresponding to those under Article 14 of Regulation (EC) No 2100/94. </inglise>
<eesti> Erandina artiklitest 8 ja 9 t&auml;hendab patendi valdaja poolt v&otilde;i tema n&otilde;usolekul talupidajale p&otilde;llumajanduslikuks kasutuseks taimse paljundusmaterjali m&uuml;&uuml;k v&otilde;i muu kauplemisviisi teel loovutamine seda, et talupidajal lubatakse oma saagi toodet kasutada talumajapidamises generatiivseks v&otilde;i vegetatiivseks paljunduseks, mille puhul selle erandi m&auml;&auml;r ja tingimused vastavad m&auml;&auml;ruse (E&Uuml;) nr 2100/94 artiklis 14 s&auml;testatutele. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> By way of derogation from Articles 8 and 9, the sale or any other form of commercialisation of breeding stock or other animal reproductive material to a farmer by the holder of the patent or with his consent implies authorisation for the farmer to use the protected livestock for an agricultural purpose. </inglise>
<eesti> Erandina artiklite 8 ja 9 s&auml;tetest t&auml;hendab patendi valdaja poolt v&otilde;i tema n&otilde;usolekul talupidajale paljunduskarja v&otilde;i muu loomse paljundusmaterjali m&uuml;&uuml;k v&otilde;i muu kauplemisviisi teel loovutamine seda, et talupidajal lubatakse kasutada kaitstud karja p&otilde;llumajanduslikul eesm&auml;rgil. </eesti>
<inglise> This includes making the animal or other animal reproductive material available for the purposes of pursuing his agricultural activity but not sale within the framework or for the purpose of a commercial reproduction activity. </inglise>
<eesti> Loas sisaldub loomade v&otilde;i muu loomse paljundusmaterjali tegemine k&auml;ttesaadavaks p&otilde;llumajanduskasutusele, kuid mitte m&uuml;&uuml;k erialase loomakasvatuse raames v&otilde;i eesm&auml;rgil. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> The extent and the conditions of the derogation provided for in paragraph 2 shall be determined by national laws, regulations and practices. </inglise>
<eesti> L&otilde;ikes 2 s&auml;testatud erandi m&auml;&auml;r ja tingimused m&auml;&auml;ratakse kindlaks siseriiklike &otilde;igusaktide ja tavadega. </eesti>
<inglise> CHAPTER III </inglise>
<eesti> III PEAT&Uuml;KK </eesti>
<inglise> Compulsory cross-licensing </inglise>
<eesti> Sund- ja ristlitsents </eesti>
<inglise> Article 12 </inglise>
<eesti> Artikkel 12 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Where a breeder cannot acquire or exploit a plant variety right without infringing a prior patent, he may apply for a compulsory licence for non-exclusive use of the invention protected by the patent inasmuch as the licence is necessary for the exploitation of the plant variety to be protected, subject to payment of an appropriate royalty. </inglise>
<eesti> Kui sordiaretaja ei saa varasemat patenti rikkumata omandada v&otilde;i kasutada taimesordi&otilde;igust, v&otilde;ib ta asjakohase litsentsitasu eest taotleda sundlitsentsi patendiga kaitstud leiutise mitteainu&otilde;iguslikuks kasutuseks niiv&otilde;rd, kui litsents on vajalik kaitstava taimesordi kasutamiseks. </eesti>
<inglise> Member States shall provide that, where such a licence is granted, the holder of the patent will be entitled to a cross-licence on reasonable terms to use the protected variety. </inglise>
<eesti> Liikmesriigid s&auml;testavad, et sellise litsentsi andmise puhul on patendi valdajal &otilde;igus saada p&otilde;hjendatud tingimustel ristlitsents kaitstud sordi kasutamiseks. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Where the holder of a patent concerning a biotechnological invention cannot exploit it without infringing a prior plant variety right, he may apply for a compulsory licence for non-exclusive use of the plant variety protected by that right, subject to payment of an appropriate royalty. </inglise>
<eesti> Kui biotehnoloogialeiutist k&auml;sitleva patendi valdaja ei saa seda kasutada ilma varasemat taimesordi&otilde;igust rikkumata, v&otilde;ib ta asjakohase litsentsitasu eest taotleda sundlitsentsi selle &otilde;igusega kaitstud taimesordi mitteainu&otilde;iguslikuks kasutamiseks. </eesti>
<inglise> Member States shall provide that, where such a licence is granted, the holder of the variety right will be entitled to a cross-licence on reasonable terms to use the protected invention. </inglise>
<eesti> Liikmesriigid s&auml;testavad, et sellise litsentsi andmise puhul on sordi&otilde;iguse valdajal &otilde;igus saada p&otilde;hjendatud tingimustel ristlitsents kaitstud leiutise kasutamiseks. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> Applicants for the licences referred to in paragraphs 1 and 2 must demonstrate that: </inglise>
<eesti> L&otilde;ikudes 1 ja 2 viidatud litsentside taotlejad peavad t&otilde;endama, et: </eesti>
<inglise> (a) they have applied unsuccessfully to the holder of the patent or of the plant variety right to obtain a contractual licence; </inglise>
<eesti> a) nad on edutult taotlenud patendi v&otilde;i taimesordi&otilde;iguse valdajalt litsentsilepingu alusel; </eesti>
<inglise> (b) the plant variety or the invention constitutes significant technical progress of considerable economic interest compared with the invention claimed in the patent or the protected plant variety. </inglise>
<eesti> b) taimesort v&otilde;i leiutis esindab m&auml;rkimisv&auml;&auml;rset tehnilist arengut, millest seoses patenditaotluses osutatud leiutusega v&otilde;i kaitstud taimesordiga johtub oluline majanduslik huvi. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> Each Member State shall designate the authority or authorities responsible for granting the licence. </inglise>
<eesti> Iga liikmesriik m&auml;&auml;rab litsentsi andmise eest vastutava ametiasutuse v&otilde;i -asutused. </eesti>
<inglise> Where a licence for a plant variety can be granted only by the Community Plant Variety Office, Article 29 of Regulation (EC) No 2100/94 shall apply. </inglise>
<eesti> Kui taimesordi kohta v&otilde;ib litsentsi v&auml;lja anda ainult &uuml;henduse sordiamet, kohaldatakse m&auml;&auml;ruse (E&Uuml;) nr 2100/94 artiklit 29. </eesti>
<inglise> CHAPTER IV </inglise>
<eesti> IV PEAT&Uuml;KK </eesti>
<inglise> Deposit, access and re-deposit of a biological material </inglise>
<eesti> Bioloogilise materjali deponeerimine, juurdep&auml;&auml;s sellele ja taasdeponeerimine </eesti>
<inglise> Article 13 </inglise>
<eesti> Artikkel 13 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Where an invention involves the use of or concerns biological material which is not available to the public and which cannot be described in a patent application in such a manner as to enable the invention to be reproduced by a person skilled in the art, the description shall be considered inadequate for the purposes of patent law unless: </inglise>
<eesti> Kui leiutis k&auml;sitleb avalikkusele k&auml;ttesaamatut bioloogilist materjali, mida ei saa patenditaotluses kirjeldada viisil, mis v&otilde;imaldaks vastava ala asjatundjal leiutist ellu viia, v&otilde;i kui leiutis h&otilde;lmab niisuguse bioloogilise materjali kasutamist, loetakse kirjeldust patendiseaduse kohaldamisel ebapiisavaks, kui: </eesti>
<inglise> (a) the biological material has been deposited no later than the date on which the patent application was filed with a recognised depositary institution. </inglise>
<eesti> a) bioloogiline materjal ei ole deponeeritud tunnustatud hoiustamisasutusse hiljemalt patenditaotluse esitamise kuup&auml;eval. </eesti>
<inglise> At least the international depositary authorities which acquired this status by virtue of Article 7 of the Budapest Treaty of 28 April 1977 on the international recognition of the deposit of micro-organisms for the purposes of patent procedure, hereinafter referred to as the 'Budapest Treaty', shall be recognised; </inglise>
<eesti> Tunnustatakse ainult neid rahvusvahelisi hoiustamisasutusi, kes said selle staatuse 28. aprillil 1977 s&otilde;lmitud mikroorganismide patendiekspertiisiks deponeerimise rahvusvahelise tunnustamise Budapesti lepingu (edaspidi "Budapesti leping") artikli 7 alusel; </eesti>
<inglise> (b) the application as filed contains such relevant information as is available to the applicant on the characteristics of the biological material deposited; </inglise>
<eesti> b) esitatud taotlus ei sisalda niisugust deponeeritud bioloogilise materjali omadustega seotud asjakohast teavet, mis on patendi taotlejale k&auml;ttesaadav; </eesti>
<inglise> (c) the patent application states the name of the depository institution and the accession number. </inglise>
<eesti> c) patenditaotluses ei n&auml;idata &auml;ra hoiustamisasutuse nime ja hoiuse numbrit. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Access to the deposited biological material shall be provided through the supply of a sample: </inglise>
<eesti> Deponeeritud bioloogilisest materjalist v&otilde;ivad saada n&auml;ite: </eesti>
<inglise> (a) up to the first publication of the patent application, only to those persons who are authorised under national patent law; </inglise>
<eesti> a) kuni patenditaotluse esimese avaldamiseni ainult need isikud, kellel siseriikliku patendi&otilde;iguse alusel on selleks luba; </eesti>
<inglise> (b) between the first publication of the application and the granting of the patent, to anyone requesting it or, if the applicant so requests, only to an independent expert; </inglise>
<eesti> b) taotluse esimese avaldamise ja patendi andmise vahel iga&uuml;ks, kes seda taotleb, v&otilde;i patendi taotleja n&otilde;udel ainult s&otilde;ltumatu ekspert; </eesti>
<inglise> (c) after the patent has been granted, and notwithstanding revocation or cancellation of the patent, to anyone requesting it. </inglise>
<eesti> c) p&auml;rast patendi andmist iga&uuml;ks, kes seda taotleb, hoolimata patendi hilisemast kehtetuks tunnistamisest v&otilde;i t&uuml;histamisest. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> The sample shall be supplied only if the person requesting it undertakes, for the term during which the patent is in force: </inglise>
<eesti> Proov antakse v&auml;lja ainult siis, kui seda taotlev isik v&otilde;tab patendi kehtimisajaks kohustuse: </eesti>
<inglise> (a) not to make it or any material derived from it available to third parties; and </inglise>
<eesti> a) mitte teha proovi v&otilde;i &uuml;ksk&otilde;ik missugust sellest saadud materjali k&auml;ttesaadavaks kolmandatele isikutele ning </eesti>
<inglise> (b) not to use it or any material derived from it except for experimental purposes, unless the applicant for or proprietor of the patent, as applicable, expressly waives such an undertaking. </inglise>
<eesti> b) mitte kasutada proovi v&otilde;i &uuml;ksk&otilde;ik missugust sellest saadud materjali muul kui katse-eesm&auml;rgil, kui patendi taotleja v&otilde;i selle valdaja selges&otilde;naliselt ei loobu sellise kohustuse n&otilde;udmisest. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> At the applicant's request, where an application is refused or withdrawn, access to the deposited material shall be limited to an independent expert for 20 years from the date on which the patent application was filed. </inglise>
<eesti> Kui taotlust ei rahuldata v&otilde;i v&otilde;etakse tagasi, lubatakse patendi taotleja n&otilde;udmisel alates taotluse sisseandmise kuup&auml;evast 20 aasta jooksul deponeeritud materjali juurde ainult s&otilde;ltumatut eksperti. </eesti>
<inglise> In that case, paragraph 3 shall apply. </inglise>
<eesti> Sel juhul kohaldatakse l&otilde;iget 3. </eesti>
<inglise> 5. </inglise>
<eesti> 5. </eesti>
<inglise> The applicant's requests referred to in point (b) of paragraph 2 and in paragraph 4 may only be made up to the date on which the technical preparations for publishing the patent application are deemed to have been completed. </inglise>
<eesti> L&otilde;ike 2 punktis b ja l&otilde;ikes 4 viidatud patendi taotleja n&otilde;uet v&otilde;ib esitada ainult kuup&auml;evani, mil patenditaotluse avaldamiseks tehtud tehnilised ettevalmistused loetakse l&otilde;petatuks. </eesti>
<inglise> Article 14 </inglise>
<eesti> Artikkel 14 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> If the biological material deposited in accordance with Article 13 ceases to be available from the recognised depositary institution, a new deposit of the material shall be permitted on the same terms as those laid down in the Budapest Treaty. </inglise>
<eesti> Kui artikli 13 kohaselt deponeeritud bioloogiline materjal ei ole enam tunnustatud hoiustamisasutuses k&auml;ttesaadav, lubatakse materjali uut deponeerimist Budapesti lepingus s&auml;testatud tingimustel. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Any new deposit shall be accompanied by a statement signed by the depositor certifying that the newly deposited biological material is the same as that originally deposited. </inglise>
<eesti> Igale uuele hoiusele pannakse kaasa hoiustaja allakirjutatud avaldus, millega t&otilde;endatakse, et uuesti deponeeritav bioloogiline materjal on sama mis esialgu deponeeritud materjal. </eesti>
<inglise> CHAPTER V </inglise>
<eesti> V PEAT&Uuml;KK </eesti>
<inglise> Final provisions </inglise>
<eesti> L&otilde;pps&auml;tted </eesti>
<inglise> Article 15 </inglise>
<eesti> Artikkel 15 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive not later than 30 July 2000. </inglise>
<eesti> Liikmesriigid j&otilde;ustavad k&auml;esoleva direktiivi j&auml;rgimiseks vajalikud &otilde;igus- ja haldusnormid hiljemalt 30. juulil 2000. </eesti>
<inglise> They shall forthwith inform the Commission thereof. </inglise>
<eesti> Liikmesriigid teatavad sellest viivitamata komisjonile. </eesti>
<inglise> When Member States adopt these measures, they shall contain a reference to this Directive or shall be accompanied by such reference on the occasion of their official publication. </inglise>
<eesti> Kui liikmesriigid need meetmed vastu v&otilde;tavad, lisavad nad nendesse meetmetesse v&otilde;i nende ametliku avaldamise korral nende juurde viite k&auml;esolevale direktiivile. </eesti>
<inglise> The methods of making such reference shall be laid down by Member States. </inglise>
<eesti> Viitamise viisi n&auml;eb ette liikmesriik. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Member States shall communicate to the Commission the text of the provisions of national law which they adopt in the field covered by this Directive. </inglise>
<eesti> Liikmesriigid edastavad komisjonile k&auml;esoleva direktiiviga reguleeritavas valdkonnas nende poolt vastuv&otilde;etavate siseriiklike &otilde;igusnormide teksti. </eesti>
<inglise> Article 16 </inglise>
<eesti> Artikkel 16 </eesti>
<inglise> The Commission shall send the European Parliament and the Council: </inglise>
<eesti> Komisjon saadab Euroopa Parlamendile ja n&otilde;ukogule: </eesti>
<inglise> (a) every five years as from the date specified in Article 15(1) a report on any problems encountered with regard to the relationship between this Directive and international agreements on the protection of human rights to which the Member States have acceded; </inglise>
<eesti> a) iga viie aasta j&auml;rel alates artikli 15 l&otilde;ikes 1 m&auml;&auml;ratletud kuup&auml;evast aruande k&otilde;ikide tekkinud probleemide kohta, pidades silmas seost k&auml;esoleva direktiivi ja inim&otilde;iguste kaitset k&auml;sitlevate rahvusvaheliste kokkulepete vahel, millega liikmesriigid on liitunud; </eesti>
<inglise> (b) within two years of entry into force of this Directive, a report assessing the implications for basic genetic engineering research of failure to publish, or late publication of, papers on subjects which could be patentable; </inglise>
<eesti> b) kahe aasta jooksul alates k&auml;esoleva direktiivi j&otilde;ustumisest aruande, milles hinnatakse m&otilde;ju, mida geenitehnika fundamentaaluuringutele avaldab see, et dokumendid, mille objektid v&otilde;iksid olla patenditavd, j&auml;&auml;vad avaldamata v&otilde;i nende avaldamine viibib; </eesti>
<inglise> (c) annually as from the date specified in Article 15(1), a report on the development and implications of patent law in the field of biotechnology and genetic engineering. </inglise>
<eesti> c) igal aastal alates artikli 15 l&otilde;ikes 1 m&auml;&auml;ratletud kuup&auml;evast aruande patendi&otilde;iguse arengu ja t&auml;henduse kohta biotehnoloogia ja geenitehnika valdkonnas. </eesti>
<inglise> Article 17 </inglise>
<eesti> Artikkel 17 </eesti>
<inglise> This Directive shall enter into force on the day of its publication in the Official Journal of the European Communities. </inglise>
<eesti> K&auml;esolev direktiiv j&otilde;ustub Euroopa &Uuml;henduste Teatajas avaldamise p&auml;eval. </eesti>
<inglise> Article 18 </inglise>
<eesti> Artikkel 18 </eesti>
<inglise> This Directive is addressed to the Member States. </inglise>
<eesti> K&auml;esolev direktiiv on adresseeritud liikmesriikidele. </eesti>
<inglise> Done at Brussels, 6 July 1998. </inglise>
<eesti> Br&uuml;ssel, 6. juuli 1998 </eesti>
<inglise> For the European Parliament </inglise>
<eesti> Euroopa Parlamendi nimel </eesti>
<inglise> The President </inglise>
<eesti> eesistuja </eesti>
<inglise> J. M. GIL-ROBLES </inglise>
<eesti> J. M. J. M. GIL-ROBLES </eesti>
<inglise> For the Council </inglise>
<eesti> N&otilde;ukogu nimel </eesti>
<inglise> The President </inglise>
<eesti> eesistuja </eesti>
<inglise> R. EDLINGER </inglise>
<eesti> R. EDLINGER </eesti>
<inglise> (1) OJ C 296, 8.10.1996, p. 4 and OJ C 311, 11.10.1997, p. 12. </inglise>
<eesti> (1) E&Uuml;T C 296, 8.10.1996, lk 4 ja E&Uuml;T C 311, 11.10.1997, lk 12. </eesti>
<inglise> (2) OJ C 295, 7.10.1996, p. 11. </inglise>
<eesti> (2) E&Uuml;T C 295, 7.10.1996, lk 11. </eesti>
<inglise> (3) Opinion of the European Parliament of 16 July 1997 (OJ C 286, 22.9.1997, p. 87). </inglise>
<eesti> (3) Euroopa Parlamendi 16. juuli 1997. aasta arvamus (E&Uuml;T C 286, 22.09.1997, lk 87). </eesti>
<inglise> Council Common Position of 26 February 1998 (OJ C 110, 8.4.1998, p. 17) and Decision of the European Parliament of 12 May 1998 (OJ C 167, 1.6.1998). </inglise>
<eesti> N&otilde;ukogu 26. veebruari 1998. aasta &uuml;hisseisukoht (E&Uuml;T C 110, 8. 04. 1998, lk 17) ja Euroopa Parlamendi 12. mai 1998. aasta otsus (E&Uuml;T C 167, 1. </eesti>
<inglise> Council Decision of 16 June 1998. </inglise>
<eesti> 06. 1998). N&otilde;ukogu 16. juuni 1998. aasta otsus. </eesti>
<inglise> (4) OJ C 68, 20.3.1995, p. 26. </inglise>
<eesti> (4) E&Uuml;T C 68, 20.03.1995, lk 26. </eesti>
<inglise> (5) OJ L 336, 23.12.1994, p. 213. </inglise>
<eesti> (5) E&Uuml;T L 336, 23.12.1994, lk 213. </eesti>
<inglise> (6) OJ L 227, 1.9.1994, p. 1. Regulation as amended by Regulation (EC) No 2506/95 (OJ L 258, 28.10.1995, p. 3). </inglise>
<eesti> (6) E&Uuml;T L 227, 1.09.1994, lk 1. M&auml;&auml;rust on muudetud m&auml;&auml;rusega (E&Uuml;) nr 2506/95 (E&Uuml;T L 258, 28.10.1995, lk 3). </eesti>
<inglise> (7) OJ L 309, 31.12.1993, p. 1. </inglise>
<eesti> (7) E&Uuml;T L 309, 31.12.1993, lk 1. </eesti>
 